Hongbiao Huang Selected Research

Proteasome Endopeptidase Complex (Proteasome)

9/2018	Targeting proteasome-associated deubiquitinases as a novel strategy for the treatment of estrogen receptor-positive breast cancer.
1/2018	Growth arrest and apoptosis induction in androgen receptor-positive human breast cancer cells by inhibition of USP14-mediated androgen receptor deubiquitination.
9/2017	A novel deubiquitinase inhibitor b-AP15 triggers apoptosis in both androgen receptor-dependent and -independent prostate cancers.
2/2017	Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases.
1/2017	Platinum-containing compound platinum pyrithione suppresses ovarian tumor proliferation through proteasome inhibition.
1/2017	Proteasome-associated deubiquitinase ubiquitin-specific protease 14 regulates prostate cancer proliferation by deubiquitinating and stabilizing androgen receptor.
1/2017	Bilirubin neurotoxicity is associated with proteasome inhibition.
9/2016	Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy.
2/2016	A microRNA-mediated decrease in eukaryotic initiation factor 2α promotes cell survival during PS-341 treatment.
1/2016	Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hongbiao Huang Research Topics

Disease

38	Neoplasms (Cancer) 01/2022 - 05/2009
11	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 05/2009
10	Breast Neoplasms (Breast Cancer) 01/2021 - 01/2018
7	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2021 - 01/2014
5	Hepatocellular Carcinoma (Hepatoma) 01/2019 - 05/2009
3	Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) 12/2022 - 01/2021
3	Carcinogenesis 11/2019 - 02/2016
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 08/2019 - 01/2017
3	Multiple Myeloma 02/2017 - 06/2014
2	Atherosclerosis 11/2020 - 01/2020
2	Neoplasm Metastasis (Metastasis) 01/2020 - 01/2019
2	Leukemia 09/2016 - 02/2011
2	Cardiomegaly (Heart Hypertrophy) 01/2016 - 01/2013
2	Rheumatic Fever (Acute Articular Rheumatism) 10/2014 - 07/2014
1	Fever (Fevers) 12/2022
1	Vascular Remodeling 11/2021
1	Neointima 11/2021
1	Systemic Vasculitis 01/2021
1	Brain Diseases (Brain Disorder) 01/2020
1	Alzheimer Disease (Alzheimer's Disease) 01/2020
1	Kernicterus 01/2020
1	Colorectal Neoplasms (Colorectal Cancer) 04/2019
1	Liver Neoplasms (Liver Cancer) 01/2019

Drug/Important Bio-Agent (IBA)

25	Proteasome Endopeptidase Complex (Proteasome)IBA 09/2018 - 05/2009
18	Deubiquitinating EnzymesIBA 01/2022 - 06/2014
9	Proteins (Proteins, Gene)FDA Link 01/2021 - 05/2009
7	UbiquitinIBA 01/2022 - 05/2009
7	Androgen Receptors (Androgen Receptor)IBA 01/2021 - 01/2017
7	Proteasome InhibitorsIBA 01/2019 - 02/2011
7	Bortezomib (Velcade)FDA Link 09/2018 - 01/2012
7	gambogic acidIBA 04/2015 - 02/2011
6	CaspasesIBA 09/2017 - 01/2014
5	AndrogensIBA 01/2022 - 01/2017
5	Ubiquitin-Specific ProteasesIBA 11/2021 - 01/2016
5	Estrogen ReceptorsIBA 01/2021 - 01/2018
5	Auranofin (Ridaura)FDA Link 03/2019 - 07/2014
4	Antineoplastic Agents (Antineoplastics)IBA 01/2019 - 02/2011
4	Imatinib Mesylate (Gleevec)FDA Link 01/2017 - 01/2014
3	bcr-abl Fusion ProteinsIBA 01/2019 - 01/2014
3	Reactive Oxygen Species (Oxygen Radicals)IBA 09/2017 - 04/2014
3	platinum pyrithioneIBA 01/2017 - 09/2016
3	Ubiquitinated ProteinsIBA 01/2017 - 05/2009
3	ATP dependent 26S protease (26S proteasome)IBA 09/2016 - 05/2009
3	GoldIBA 01/2016 - 07/2014
2	Intravenous Immunoglobulins (IVIG)FDA Link 12/2022 - 07/2021
2	Tamoxifen FDA LinkGeneric 01/2021 - 01/2020
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 11/2016
2	LigandsIBA 01/2021 - 01/2020
2	CD36 AntigensIBA 11/2020 - 01/2020
2	BilirubinIBA 01/2020 - 01/2017
2	Biological ProductsIBA 01/2020 - 02/2011
2	ErbB Receptors (EGF Receptor)IBA 08/2019 - 04/2019
2	enzalutamideIBA 05/2019 - 04/2019
2	Therapeutic UsesIBA 09/2017 - 09/2016
2	benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketoneIBA 09/2017 - 01/2016
2	Acetylcysteine (Siran)FDA LinkGeneric 09/2017 - 04/2014
2	Platinum Compounds (Compounds, Platinum)IBA 01/2017 - 09/2016
2	PlatinumIBA 01/2017 - 09/2016
2	Peptide Hydrolases (Proteases)FDA Link 01/2017 - 06/2014
2	Cisplatin (Platino)FDA LinkGeneric 01/2017 - 09/2016
2	DNA (Deoxyribonucleic Acid)IBA 01/2017 - 09/2016
2	pyrithioneIBA 11/2016 - 01/2015
2	CopperIBA 01/2015 - 06/2014
2	Antirheumatic Agents (DMARD)IBA 10/2014 - 07/2014
2	Messenger RNA (mRNA)IBA 01/2013 - 01/2012
2	Carnitine (L-Carnitine)FDA LinkGeneric 01/2012 - 01/2012
2	Histones (Histone)IBA 01/2012 - 01/2012
2	Histone Deacetylase InhibitorsIBA 01/2012 - 01/2012
2	shikoninIBA 05/2011 - 05/2009
2	Chymotrypsin FDA Link 01/2011 - 05/2009
1	C-Reactive ProteinIBA 12/2022
1	Alkaline PhosphataseIBA 12/2022
1	SodiumIBA 12/2022
1	Serum AlbuminIBA 12/2022
1	EnzymesIBA 01/2022
1	S-Phase Kinase-Associated Proteins (Skp1 Protein)IBA 11/2021
1	SolutionsIBA 01/2021
1	Amino Acids FDA Link 01/2021
1	glucose-regulated proteinsIBA 01/2021
1	Protein Kinases (Protein Kinase)IBA 01/2021
1	diosmetinIBA 09/2020
1	Estrogens (Estrogen)FDA Link 01/2020
1	Fulvestrant (Faslodex)FDA Link 01/2020
1	Trastuzumab (Herceptin)FDA Link 01/2020
1	buteinIBA 01/2020
1	Ligases (Synthetase)IBA 01/2020
1	Lipoproteins (Lipoprotein)IBA 01/2020
1	tetrahydropalmatineIBA 01/2020
1	Molecular Chaperones (Chaperone, Molecular)IBA 01/2020
1	Ubiquitin-Specific Peptidase 7IBA 11/2019
1	Tyrosine Kinase InhibitorsIBA 08/2019
1	Small Interfering RNA (siRNA)IBA 05/2019
1	AgarIBA 05/2019
1	NF-kappa B (NF-kB)IBA 05/2019
1	spautin-1IBA 04/2019
1	RNA Precursors (Precursor, mRNA)IBA 01/2019

Therapy/Procedure

23	Therapeutics 01/2022 - 02/2011
4	Castration 01/2022 - 01/2020
3	Drug Therapy (Chemotherapy) 01/2017 - 04/2015
1	Ligation 11/2021